Clinical Trials Logo
  1. Home
  2. Oral Leukoplakia
  3. NCT00155337

Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia

Oral Leukoplakia Clinical Trial

Official title:
Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia

Clinical Trial Summary

Photodynamic therapy for oral leukoplakia and erythroleukoplakia

Clinical Trial Description

Photodynamic therapy for oral leukoplakia and erythroleukoplakia ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00155337
Study type Interventional
Source National Taiwan University Hospital
Contact
Status Completed
Phase Phase 4
Start date August 2004
Completion date December 2007
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT05505539 - Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia Phase 1
Terminated NCT00176566 - A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Completed NCT04712929 - Candida Associated Cytokines in Oral Leukoplakia
Completed NCT03031899 - Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Terminated NCT00571558 - Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia Phase 1
Recruiting NCT06321003 - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Not yet recruiting NCT04732741 - Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions
Completed NCT00369174 - Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia Phase 2
Completed NCT00099021 - Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Phase 2
Not yet recruiting NCT05727761 - Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia Phase 2
Active, not recruiting NCT02581137 - Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Phase 2
Recruiting NCT05942794 - Identification of Oral Lesions Through an Autofluorescence System N/A
Completed NCT00330382 - Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia Phase 2
Recruiting NCT05237960 - Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia Phase 2
Not yet recruiting NCT06256809 - Analyzing Handprint Patterns to Predict Oral Cancer Risks: A Comparative Study
Completed NCT00951379 - Pioglitazone for Oral Premalignant Lesions Phase 2
Recruiting NCT04251845 - Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia N/A
Terminated NCT04079491 - Intra and Extra Oral Inspection of Oral Mucosa